EHA 2022 | Safety and efficacy of REGN5458 in patients with relapsed/refractory (R/R) multiple myeloma
Joshua Richter, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, discusses the safety and efficacy of REGN5458, a BCMA, CD3-directed bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma. Dr Richter first highlights the dosing schedule used in this study, and then goes on to discuss the promising overall response rates and impressive toxicity profile of this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consultancy: Celgene/BMS, Secura Bio, Oncopeptides and Takeda; speakers bureau: Janssen, Sanofi and Adaptive Biotechnologies
Advisory Boards: Celgene/BMS, Janssen, Karyopharm, Sanofi, X4 pharmaceuticals, Oncopeptides, Adaptive Biotechnologies, Secura Bio and AstraZeneca
